Development of an effective therapeutic regime for preventing cancer recurrence after surgery using a novel viro-immunotherapeutic agent

使用新型病毒免疫治疗剂开发有效的治疗方案以预防手术后癌症复发

基本信息

  • 批准号:
    MR/M015696/1
  • 负责人:
  • 金额:
    $ 63.09万
  • 依托单位:
  • 依托单位国家:
    英国
  • 项目类别:
    Research Grant
  • 财政年份:
    2015
  • 资助国家:
    英国
  • 起止时间:
    2015 至 无数据
  • 项目状态:
    已结题

项目摘要

Despite advances in surgical techniques, survival rates for oral sqamous cell carcinoma, the most common form of oral cancer (398,000 patients worldwide in 2012), have not improved for the last 20 years. 50-70% of patients die within 5 years due to local recurrence and remote metastasis. The prognosis of patients with recurrent or metastatic head and neck squamous cell cancer is generally poor. The median survival in most series is six to nine months depending upon patient- and disease-related factors. Therefore, new approaches are urgently needed to prevent recurrence and metastasis after surgery. The main source for recurrence and metastasis after surgery is minimal residual disease (MRD) that remains in situ after surgical resection in microscopic deposits beyond the clearance margins and in micrometastases. There is increasing evidence that surgical intervention can actually promote tumour recurrence and distant metastases by several mechanisms including suppression of host immune cells, such as natural killer (NK) cells and T cells. Tumour-targeted oncolytic viruses (TOVs) are attractive therapeutics for cancer because they selectively amplify through replication and spread the input dose of virus in the target tumour and most importantly kill tumours by multiple mechanisms, in particular they can induce systemic anti-tumour immunity that can target MRD. We have recently created a novel tumour-targeted oncolytic vaccinia virus. Treatment with this virus resulted in a strong NK cell activation and potent tumour-specific immunity, and dramatically reduced lung metastasis after surgery in several cancer models when the virus was intratumurally injected before surgery. To improve its anti-tumour efficacy further, we now have engineered the mutant virus with a particular therapeutic gene that can boost the activity of NK cells and anti-tumour T cells further. In this project, we will evaluate the feasibility, efficacy and safety of this novel immunotherapeutic agent for preventing recurrence and metastasis of cancer after surgery in a serious of tumour models that can mimic the clinical situation of cancer patients. By the end of this project, an optimal therapeutic regime will be developed. These data will provide proof of concept for translation of the regime into clinical trials. This new approach may significantly improve the survival of head and neck cancer patients in the future.
尽管手术技术取得了进步,但口腔鳞状细胞癌(最常见的口腔癌形式,2012年全球有39.8万例患者)的生存率在过去20年没有改善。50-70%的患者因局部复发和远处转移而在5年内死亡。复发或转移性头颈部鳞状细胞癌患者的预后通常较差。大多数系列的中位生存期为6至9个月,取决于患者和疾病相关因素。因此,迫切需要新的方法来防止术后复发和转移。术后复发和转移的主要来源是微小残留病(MRD),其在手术切除后在清除边缘以外的显微沉积物和微转移中仍然存在。越来越多的证据表明,手术干预实际上可以通过多种机制促进肿瘤复发和远处转移,包括抑制宿主免疫细胞,如自然杀伤细胞(NK)细胞和T细胞。肿瘤靶向溶瘤病毒(tov)是一种有吸引力的癌症治疗方法,因为它们通过复制和传播输入剂量的病毒在目标肿瘤中选择性扩增,最重要的是通过多种机制杀死肿瘤,特别是它们可以诱导针对MRD的全身抗肿瘤免疫。我们最近创造了一种新的肿瘤靶向溶瘤痘苗病毒。用这种病毒治疗导致NK细胞的强烈激活和强大的肿瘤特异性免疫,并在手术前在几种癌症模型中静脉注射这种病毒,显著减少手术后的肺转移。为了进一步提高其抗肿瘤功效,我们现在已经设计了带有特定治疗基因的突变病毒,可以进一步提高NK细胞和抗肿瘤T细胞的活性。在本项目中,我们将在一系列模拟癌症患者临床情况的肿瘤模型中评估这种新型免疫治疗剂预防癌症术后复发和转移的可行性、有效性和安全性。到本项目结束时,将开发出最佳的治疗方案。这些数据将为将该疗法转化为临床试验提供概念证明。这种新方法可能在未来显著提高头颈癌患者的生存率。

项目成果

期刊论文数量(10)
专著数量(0)
科研奖励数量(0)
会议论文数量(0)
专利数量(0)
Oncolytic Viruses-Interaction of Virus and Tumor Cells in the Battle to Eliminate Cancer.
  • DOI:
    10.3389/fonc.2017.00195
  • 发表时间:
    2017
  • 期刊:
  • 影响因子:
    4.7
  • 作者:
    Howells A;Marelli G;Lemoine NR;Wang Y
  • 通讯作者:
    Wang Y
Immune-checkpoint blockade: the springboard for immuno-combination therapy.
免疫检查点阻断:免疫组合治疗的跳板。
  • DOI:
    10.1038/gt.2015.98
  • 发表时间:
    2015
  • 期刊:
  • 影响因子:
    5.1
  • 作者:
    Ibrahim AM
  • 通讯作者:
    Ibrahim AM
Deoxythymidylate Kinase as a Promising Marker for Predicting Prognosis and Immune Cell Infiltration of Pan-cancer.
{{ item.title }}
{{ item.translation_title }}
  • DOI:
    {{ item.doi }}
  • 发表时间:
    {{ item.publish_year }}
  • 期刊:
  • 影响因子:
    {{ item.factor }}
  • 作者:
    {{ item.authors }}
  • 通讯作者:
    {{ item.author }}

数据更新时间:{{ journalArticles.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ monograph.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ sciAawards.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ conferencePapers.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ patent.updateTime }}

Yaohe Wang其他文献

Interleukin-1β and tumour necrosis factor-α promote the transformation of human immortalised mesothelial cells by erionite
白细胞介素-1β和肿瘤坏死因子-α促进毛沸石转化人永生化间皮细胞
  • DOI:
  • 发表时间:
    2004
  • 期刊:
  • 影响因子:
    0
  • 作者:
    Yaohe Wang;S. Faux;G. Halldén;D. Kirn;C. E. Houghton;N. Lemoine;G. Patrick
  • 通讯作者:
    G. Patrick
CD8+ T cell response mediates the therapeutic effects of oncolytic adenovirus in an immunocompetent mouse model
CD8 T 细胞反应介导免疫活性小鼠模型中溶瘤腺病毒的治疗效果
  • DOI:
    10.1007/s11434-011-4875-3
  • 发表时间:
    2012-01
  • 期刊:
  • 影响因子:
    0
  • 作者:
    Yajun Yang;Xiaozhu Li;Yaohe Wang;Shengdian Wang
  • 通讯作者:
    Shengdian Wang
Hand1单倍剂量不足通过阻止心脏破裂提高急性心梗小鼠的生存率。
  • DOI:
  • 发表时间:
    2016
  • 期刊:
  • 影响因子:
    0
  • 作者:
    Congjia Shan;Yaohe Wang;Changsheng Ma;Jianzeng Dong
  • 通讯作者:
    Jianzeng Dong
Non-secreting IL12 expressing oncolytic adenovirus Ad-TD-nsIL12 in recurrent high-grade glioma: a phase I trial
在复发性高级别胶质瘤中表达非分泌型白细胞介素 12 的溶瘤腺病毒 Ad-TD-nsIL12:一项 I 期试验
  • DOI:
    10.1038/s41467-024-53041-7
  • 发表时间:
    2024-11-08
  • 期刊:
  • 影响因子:
    15.700
  • 作者:
    Weihai Ning;Xiao Qian;Louisa Chard Dunmall;Funan Liu;Yuduo Guo;Shenglun Li;Dixiang Song;Deshan Liu;Lixin Ma;Yanming Qu;Haoran Wang;Chunyu Gu;Mingshan Zhang;Yaohe Wang;Shengdian Wang;Hongwei Zhang
  • 通讯作者:
    Hongwei Zhang
COVID-19 Resulting in Potential Hearing Damage of Rodents
COVID-19 可能导致啮齿类动物听力受损
  • DOI:
    10.1055/s-0042-1747915
  • 发表时间:
    2022
  • 期刊:
  • 影响因子:
    0
  • 作者:
    Jinxin Miao;Hongen Xu;Yongan Tian;Jianyao Wang;Wenxue Tang;Yaohe Wang;Mingsan Miao;Jianbo Liu;Xia Xue;Yongjun Guo
  • 通讯作者:
    Yongjun Guo

Yaohe Wang的其他文献

{{ item.title }}
{{ item.translation_title }}
  • DOI:
    {{ item.doi }}
  • 发表时间:
    {{ item.publish_year }}
  • 期刊:
  • 影响因子:
    {{ item.factor }}
  • 作者:
    {{ item.authors }}
  • 通讯作者:
    {{ item.author }}

{{ truncateString('Yaohe Wang', 18)}}的其他基金

Pre-clinical development for IND application of a novel systemically deliverable oncolytic Vaccinia virus for treatment of pancreatic cancer
新型可全身给药的溶瘤牛痘病毒用于治疗胰腺癌的 IND 应用的临床前开发
  • 批准号:
    MR/V006053/1
  • 财政年份:
    2021
  • 资助金额:
    $ 63.09万
  • 项目类别:
    Research Grant

相似国自然基金

多跳无线 MESH 网络中 QoS 保障算法的研究设计和性能分析
  • 批准号:
    60902041
  • 批准年份:
    2009
  • 资助金额:
    20.0 万元
  • 项目类别:
    青年科学基金项目

相似海外基金

Regulation of human tendon development and regeneration
人体肌腱发育和再生的调节
  • 批准号:
    10681951
  • 财政年份:
    2023
  • 资助金额:
    $ 63.09万
  • 项目类别:
Development of CM-CS1 CAR Treg to Treat Amyotrophic Lateral Sclerosis (ALS)
开发 CM-CS1 CAR Treg 治疗肌萎缩侧索硬化症 (ALS)
  • 批准号:
    10696512
  • 财政年份:
    2023
  • 资助金额:
    $ 63.09万
  • 项目类别:
Development of miR-27a* for the Treatment of Head and Neck Squamous Cell Carcinoma
开发 miR-27a* 用于治疗头颈鳞状细胞癌
  • 批准号:
    10752726
  • 财政年份:
    2023
  • 资助金额:
    $ 63.09万
  • 项目类别:
The roles of AP-1 pathway activation in NK cell development and exhaustion programming in AML
AP-1 通路激活在 NK 细胞发育和 AML 衰竭编程中的作用
  • 批准号:
    10751755
  • 财政年份:
    2023
  • 资助金额:
    $ 63.09万
  • 项目类别:
Ex vivo whole ovary culture system for screening gonadotoxicity during drug development
用于在药物开发过程中筛选性腺毒性的离体全卵巢培养系统
  • 批准号:
    10823136
  • 财政年份:
    2023
  • 资助金额:
    $ 63.09万
  • 项目类别:
Mechanism of Transcriptional Regulation of Th2 Cell Development
Th2细胞发育的转录调控机制
  • 批准号:
    10716014
  • 财政年份:
    2023
  • 资助金额:
    $ 63.09万
  • 项目类别:
Development of a Piezoelectric Intramedullary Nail for Enhanced Fracture Healing
开发用于增强骨折愈合的压电髓内钉
  • 批准号:
    10759862
  • 财政年份:
    2023
  • 资助金额:
    $ 63.09万
  • 项目类别:
Development of peptide drug conjugates for cancer therapy
开发用于癌症治疗的肽药物缀合物
  • 批准号:
    10760236
  • 财政年份:
    2023
  • 资助金额:
    $ 63.09万
  • 项目类别:
Severe neonatal hyperbilirubinemia (SNH) and the expression of UDP-glucuronosyltransferase 1A1 (UGT1A1) play key roles in the development of necrotizing enterocolitis (NEC)
严重新生儿高胆红素血症 (SNH) 和 UDP-葡萄糖醛酸基转移酶 1A1 (UGT1A1) 的表达在坏死性小肠结肠炎 (NEC) 的发生中起关键作用
  • 批准号:
    10713549
  • 财政年份:
    2023
  • 资助金额:
    $ 63.09万
  • 项目类别:
Growth hormone regulating chondrocyte metabolism for osteoarthritis development
生长激素调节软骨细胞代谢促进骨关节炎的发展
  • 批准号:
    10730575
  • 财政年份:
    2023
  • 资助金额:
    $ 63.09万
  • 项目类别:
{{ showInfoDetail.title }}

作者:{{ showInfoDetail.author }}

知道了